Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study
Jesús García-Donás(Universidad San Pablo CEU), Cristina Rodríguez‐Antona(Instituto de Salud Carlos III), Begoña Mellado(Hospital Clínic de Barcelona), Daniel Castellano(Universidad Complutense de Madrid), Aranzazu González del Alba(Hospital Universitario Son Espases), Fernando Moreno(Hospital Clínico San Carlos), Emilio Esteban(Hospital Universitario Central de Asturias), Mercedes Robledo(The University of Texas at San Antonio Health Science Center), Javier Puente(Hospital Clínico San Carlos), Joaquim Bellmunt(Dana-Farber Cancer Institute), Enrique Gallardo(Marqués de Valdecilla University Hospital), Esther Martínez(Complejo Hospitalario de Jaén), Miguel Ángel Climent(Radboud University Nijmegen), Luis J. Leandro‐García(Spanish National Cancer Research Centre), Albert Font(Marqués de Valdecilla University Hospital), José Ángel Arranz(Hospital General Universitario Gregorio Marañón)
Cited by 221
Related Papers
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k